P01.066 Patients with EGFR amplification but without EGFRvIII expression have improved benefit compared to those with EGFRvIII expression in samples of the INTELLANCE 2/EORTC 1410 randomized phase II trial

BACKGROUND: Depatux-M is an antibody-drug-conjugate consisting of an antibody (ABT-806) bound to the toxin monomethylauristatin-F. A randomized phase II trial on EGFR-amplified recurrent glioblastomas (GBMs) showed a significant improvement (p=0.06 in the primary analysis, p=0.024 in follow-up analy...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Neuro Oncol
Hoofdauteurs: French, P J, Kros, J, de Heer, I, Ansell, P, Looman, J, Bain, E, Morfouace, M, Gorlia, T, Golfinopoulos, V, van den Bent, M
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Oxford University Press 2018
Onderwerpen:
Poster Presentations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6144572/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noy139.108
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items